Cargando…

Efficacy and safety of intravenous recombinant tissue plasminogen activator in mild ischaemic stroke: a meta-analysis

The benefits and safety of intravenous recombinant tissue plasminogen activator (IV-tPA) for patients with mild ischaemic stroke (MIS) are still unclear. The objective of this meta-analysis was to evaluate the efficacy and safety of IV-tPA as treatment for patients with MIS. We performed a systemati...

Descripción completa

Detalles Bibliográficos
Autores principales:	You, Shoujiang, Saxena, Anubhav, Wang, Xia, Tan, WeeYong, Han, Qiao, Cao, Yongjun, Liu, Chun-Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870640/ https://www.ncbi.nlm.nih.gov/pubmed/29600004 http://dx.doi.org/10.1136/svn-2017-000106

Ejemplares similares

Current status of intravenous tissue plasminogen activator dosage for acute ischaemic stroke: an updated systematic review
por: Wang, Xia, et al.
Publicado: (2018)

A literature review of cost-effectiveness of intravenous recombinant tissue plasminogen activator for treating acute ischaemic stroke
por: Joo, Heesoo, et al.
Publicado: (2017)

Intravenous recombinant tissue plasminogen activator for acute ischemic stroke: a feasibility and safety study
por: Sadeghi-Hokmabadi, Elyar, et al.
Publicado: (2016)

Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis
por: Wardlaw, Joanna M, et al.
Publicado: (2012)

Low-dose intravenous tissue plasminogen activator for acute ischaemic stroke: an alternative or a new standard?
por: Dong, Yi, et al.
Publicado: (2016)

Risk factors of haemorrhagic transformation for acute ischaemic stroke in Chinese patients receiving intravenous recombinant tissue plasminogen activator: a systematic review and meta-analysis
por: Guo, Yijia, et al.
Publicado: (2018)

The Chinese Stroke Association scientific statement: intravenous thrombolysis in acute ischaemic stroke
por: Dong, Qiang, et al.
Publicado: (2017)

The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial
Publicado: (2012)

Use of intravenous tissue plasminogen activator and hospital costs for patients with acute ischaemic stroke aged 18–64 years in the USA
por: Joo, Heesoo, et al.
Publicado: (2016)

Racial Disparities in Intravenous Recombinant Tissue Plasminogen Activator Use Persist at Primary Stroke Centers
por: Aparicio, Hugo J., et al.
Publicado: (2015)

Predictors of Intracerebral Hemorrhage in Acute Stroke Patients Receiving Intravenous Recombinant Tissue Plasminogen Activator
por: Chenna, Vijay, et al.
Publicado: (2018)

Comparison of outcome of patients with acute minor ischaemic stroke treated with intravenous t-PA, DAPT or aspirin
por: Wang, Peng, et al.
Publicado: (2020)

Ischaemic stroke and the recanalization drug tissue plasminogen activator interfere with antibacterial phagocyte function
por: Vogelgesang, Antje, et al.
Publicado: (2017)

Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator for Ischemic Stroke Patients over 80 Years Old: The Fukuoka Stroke Registry
por: Matsuo, Ryu, et al.
Publicado: (2014)

Intravenous Recombinant Tissue Plasminogen Activator Thrombolysis in a Patient with Acute Ischemic Stroke Secondary to Aortic Dissection
por: Hong, Keun-Sik, et al.
Publicado: (2009)

Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke
por: Chapman, Sherita N, et al.
Publicado: (2014)

Does Intravenous Administration of Recombinant Tissue Plasminogen Activator for Ischemic Stroke can Cause Inferior Myocardial Infarction?
por: Almasi, Mostafa, et al.
Publicado: (2016)

Carotid Artery Stenting for Acute Ischemic Stroke Patients after Intravenous Recombinant Tissue Plasminogen Activator Treatment
por: Deguchi, Ichiro, et al.
Publicado: (2016)

Age-specific Cost Effectiveness of Using Intravenous Recombinant Tissue Plasminogen Activator for Treating Acute Ischemic Stroke
por: Joo, Heesoo, et al.
Publicado: (2017)

Intravenous Thrombolysis in Chinese Patients with Different Subtype of Mild Stroke: Thrombolysis in Patients with Mild Stroke
por: Chen, Weiqi, et al.
Publicado: (2017)

Intravenous thrombolysis in Chinese patients with mild acute ischemic stroke
por: Xiong, Yunyun, et al.
Publicado: (2021)

Emergent Double-barrel Bypass Shortly after Intravenous Administration of Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke
por: Choi, Joon-Ho, et al.
Publicado: (2016)

The Utility of Automated ASPECTS in Acute Ischemic Stroke for Intravenous Recombinant Tissue Plasminogen Activator (IV-rtPA) Therapy
por: Shibata, Soichiro, et al.
Publicado: (2022)

Intravenous thrombolysis in the emergency department for the treatment of acute ischaemic stroke
por: Semplicini, A, et al.
Publicado: (2008)

Comparison of Effectiveness and Safety of Low-Dose Versus Standard-Dose Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke: A Meta-Analysis
por: Karedath, Jithin, et al.
Publicado: (2023)

Secondary prevention medication persistence and prognosis of acute ischaemic stroke or transient ischaemic attack
por: Zhang, Lei, et al.
Publicado: (2021)

Intravenous tissue plasminogen activator, ischemic stroke, and the risk of Kounis Syndrome
por: Kounis, Nicholas G., et al.
Publicado: (2011)

CO(2) combining power and outcomes in patients with acute ischaemic stroke or transient ischaemic attack
por: Wang, Anxin, et al.
Publicado: (2020)

Efficacy of Urinary Kallidinogenase Plus Intravenous Recombinant Tissue Plasminogen Activator for Stroke Patients With Extended Window: A Retrospective Analysis
por: Li, Xueyuan, et al.
Publicado: (2023)

Baseline brain imaging signs in patients with ischaemic stroke by the presence of atrial fibrillation: the ENCHANTED trial
por: Wang, Xia, et al.
Publicado: (2023)

Evaluation of Cerebral Perfusion in Patients Undergoing Intravenous Recombinant Tissue Plasminogen Activator Thrombolysis
por: HIRANO, Teruyuki
Publicado: (2015)

A Retrospective Study of thrombolysis with 0.6 mg/kg Recombinant Tissue Plasminogen Activator (rt-PA) in Mild Stroke
por: Yang, Jie, et al.
Publicado: (2016)

Unruptured Cerebral Aneurysm Detected after Intravenous Tissue Plasminogen Activator for Stroke
por: Yoneda, Yukihiro, et al.
Publicado: (2009)

Medicolegal Considerations with Intravenous Tissue Plasminogen Activator in Stroke: A Systematic Review
por: Bhatt, Archit, et al.
Publicado: (2013)

Intravenous Tissue Plasminogen Activator for an Ischemic Stroke with Occult Double Primary Cancer
por: Yoneda, Yukihiro, et al.
Publicado: (2014)

Cost-effectiveness of recombinant tissue-type plasminogen activator for acute ischaemic stroke with unknown time of onset: a Markov modelling analysis from the Chinese and US perspectives
por: Zhao, Songfeng, et al.
Publicado: (2022)

Functional status at 30 and 90 days after mild ischaemic stroke
por: Gardener, Hannah, et al.
Publicado: (2022)

Homocystinuria with Cerebral Venous Sinus Thrombosis: Excellent Recovery with Intravenous Recombinant Tissue Plasminogen Activator
por: Gowda, Vykuntaraju K, et al.
Publicado: (2017)

Concurrent intracranial and extracranial artery stenosis and the prognosis of transient ischaemic symptoms or imaging-negative ischaemic stroke
por: Suo, Yue, et al.
Publicado: (2020)

Clinical safety and outcome of recombinant tissue plasminogen activator in patients with stroke attributable to small artery occlusion: A protocol for systematic review and meta-analysis
por: Ni, Li-Yan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ahphcds06csaokd9u9n7l1lhk0